|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011615,
umls-concept:C0030705,
umls-concept:C0034380,
umls-concept:C0087111,
umls-concept:C0205164,
umls-concept:C0733511,
umls-concept:C1099414,
umls-concept:C1280500,
umls-concept:C1446409,
umls-concept:C1457887,
umls-concept:C2757068
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-4-26
|
|
pubmed:abstractText |
Topical application of the calcineurin inhibitors pimecrolimus and tacrolimus is a current major advance in the therapy of atopic dermatitis. The aims of this post-marketing surveillance were: a) to acquire data on the efficacy and tolerability of pimecrolimus ointment (Elidel) on a very large cohort of patients from outpatient clinics, and b) to assess changes in their quality of life, a parameter not often considered in previous studies.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1610-0379
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
301-6
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16638059-Adolescent,
pubmed-meshheading:16638059-Calcineurin,
pubmed-meshheading:16638059-Child,
pubmed-meshheading:16638059-Child, Preschool,
pubmed-meshheading:16638059-Dermatitis, Atopic,
pubmed-meshheading:16638059-Dermatologic Agents,
pubmed-meshheading:16638059-Female,
pubmed-meshheading:16638059-Germany,
pubmed-meshheading:16638059-Humans,
pubmed-meshheading:16638059-Infant,
pubmed-meshheading:16638059-Infant, Newborn,
pubmed-meshheading:16638059-Male,
pubmed-meshheading:16638059-Prevalence,
pubmed-meshheading:16638059-Product Surveillance, Postmarketing,
pubmed-meshheading:16638059-Prognosis,
pubmed-meshheading:16638059-Quality of Life,
pubmed-meshheading:16638059-Tacrolimus,
pubmed-meshheading:16638059-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
|
|
pubmed:affiliation |
Department of Dermatology and Allergology, University of Ulm, Germany. cord.sunderkoetter@ukmuenster.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Research Support, Non-U.S. Gov't
|
